A. McCullough

Epidemiology · 2001–2014

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 94 citations into it; #505 of 2,148 by trust here, #75 by citations
• Hepatology — 29 citations into it; #122 of 151 by trust here, #10 by citations
• Pathology and Forensic Medicine — 21 citations into it

Whom A. McCullough trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. E. Brunt

Who trusts A. McCullough overall

1. V. Ratziu

Papers from A. McCullough's perspective

Ordered by how strongly the researchers A. McCullough trusts endorse each paper. Same corpus, a different order for every researcher.

1. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
2. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. (New England Journal of Medicine)
3. AGA technical review on nonalcoholic fatty liver disease. (Gastroenterology)
4. Histopathology of pediatric nonalcoholic fatty liver disease (Hepatology)
5. Metformin reverses fatty liver disease in obese, leptin-deficient mice (Nature Medicine)
6. Design and validation of a histological scoring system for nonalcoholic fatty liver disease (Hepatology)
7. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (New England Journal of Medicine)
8. Sources of Variation and Bias in Studies of Diagnostic Accuracy (Annals of Internal Medicine)
9. The utility of radiological imaging in nonalcoholic fatty liver disease. (Gastroenterology)
10. Pathology of nonalcoholic fatty liver disease. (American Journal of Clinical Pathology)

Their papers

• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014) — 2,063 citations
• ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (2011) — 738 citations
• Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010) — 3,032 citations
• Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study (2009) — 620 citations
• Long-term follow-up of patients with nonalcoholic fatty liver. (2009) — 709 citations
• In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (2006) — 697 citations
• Insulin resistance: A metabolic pathway to chronic liver disease (2005) — 920 citations
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease (2005) — 10,109 citations
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. (2001) — 2,611 citations